期刊文献+

三辨治癌合并介入治疗中晚期胃癌43例 被引量:1

43 Cases of Advanced Gastric Cancer Treated by Cancer Treatment Based on SPL Theory with Interventional Therapy
下载PDF
导出
摘要 目的:观察三辨治癌指导下参藤消胃积汤配合介入治疗中晚期胃癌的临床疗效。方法:口服参藤消胃积汤,每日1剂;同时配合介入,治疗中晚期胃癌。结果:CR+PR+NC=95.3%,中位生存期23个月,;1年生存率76.7%,2年生存率44.1%,3年生存率27.8%,4年生存率16.3%,5年生存率7.0%。结论:根据"三辨论治"即辨证论治、辨病理论治、辨病位论治,参藤消胃积汤配合介入治疗胃癌,能显著提高患者的生存质量及生存期,疗效显著。 Objective: To evaluate the clinical therapeutic effect of henteng Xiaoweiji Decoction with the interventional therapy on advanced gastric cancer under the guidance of cancer treatment based on SPL theory. Methods: Oral Shen Teng Xiaoji medicinal broth,a dose of medicine everyday,it cures advanced gastric cancer cooperating interventional therapy. Results: The effective rate of tumor changes was 95. 3% and the effective rate of quality of life was 97. 7%. MST was 23 months and one-year survival rate was 76. 7%,two-year survival rate 44. 1%,three-year survival rate 27. 8%,four-year survival rate 16. 3%,five-year survival rate 7. 0%. Conclusion: According to the cancer treatment based on SPL theory,which contains differentiation of symptoms and signs,differentiation of pathological changes and differentiation of disease locations,Shenteng Xiaoweiji Decoction with interventional therapy can significantly improve the survival quality of the advanced gastric cancer patients and extend their life span.
出处 《辽宁中医杂志》 CAS 北大核心 2015年第3期535-536,共2页 Liaoning Journal of Traditional Chinese Medicine
基金 河北省中医药管理局2013度中医药类科研计划课题(2013234)
关键词 三辨治癌 参藤消胃积汤 介入 中晚期胃癌 cancer treatment based on SPL theory Shenteng Xiaoweiji Decoction interventional therapy advanced gastric cancer
  • 相关文献

参考文献6

二级参考文献14

  • 1王济民,李佩文,侯浚,陈志峰,王俊茹,刘少翔.中医药治疗癌症疗效评定方法的研究[J].中医研究,1994,7(3):44-45. 被引量:13
  • 2罗健,孙燕.癌症患者的生活质量研究(一)[J].中国肿瘤,1995,4(10):15-19. 被引量:34
  • 3金懋林.胃癌药物治疗研究新进展[J].临床药物治疗杂志,2006,4(2):13-16. 被引量:20
  • 4秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:268
  • 5Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer ( SPI- RITS trial) : a phase Ⅲ trial[J]. Lancet Oncol,2008, 9(3) : 215 -221.
  • 6Chollet P, Schoffski P, Weigang-Kohler K, et al. Phase Ⅱ trial with S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group ( EC- SG) [J]. Eur J Cancer, 2003, 39(9) : 1264 - 1270.
  • 7Park YH, Lee JL, Ryoo BY, et al. Capecitabine in combination with oxaliplatin ( XELOX ) as a first-line therapy for advanced gastric cancer [ J ]. Cancer Chemother Pharmacol, 2008, 61 (4) : 623 - 629.
  • 8Koizumi W, Takiuchi H, Yamada Y,et al. Phase Ⅱ study of ox- aliplatin plus S-1 as first-line treatment for advanced gastric canc- er ( G-SOX study) [ J ]. Ann Oncol, 2010, 21 ( 5 ) : 1001 - 1005.
  • 9Glimelius B, Hoffman K, Haglund U, et al. Initial or delayed ehemotherapy with best supportive care in advaneed gastric cane- er[J]. Ann Oncol,1994,5(2) :189 -190.
  • 10Pyrhonen S, Kuituncn T, Nyandoto P,et al. Randomised compari- son of fluorouracil , epidoxorubicin and methotrexate ( FEMTX ) plus supportive care with supportive care alone in patients with nonresectable gastric cancer[ J]. Br J Cancer, 1995,71 ( 3 ) :587 - 591.

共引文献121

同被引文献12

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部